4.7 Article

Trends in Settings for Peripheral Vascular Intervention and the Effect of Changes in the Outpatient Prospective Payment System

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 65, Issue 9, Pages 920-927

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2014.12.048

Keywords

-

Funding

  1. American Heart Association Clinical and Mentored Population Science Research [14CRP18630003]
  2. AstraZeneca
  3. Boston Scientific
  4. Bristol-Myers Squibb
  5. American Heart Association
  6. Daiichi Sankyo
  7. American College of Cardiology
  8. Eli Lilly Co.
  9. Janssen Pharmaceutical Products
  10. Society of Thoracic Surgeons
  11. Johnson Johnson
  12. Maquet
  13. National Heart, Lung, and Blood Institute
  14. Pluristem
  15. GlaxoSmithKline
  16. Novartis
  17. Amgen

Ask authors/readers for more resources

BACKGROUND Peripheral vascular intervention (PVI) is an effective treatment option for patients with peripheral artery disease (PAD). In 2008, Medicare modified reimbursement rates to encourage more efficient outpatient use of PVI in the United States. OBJECTIVES The purpose of this study was to evaluate trends in the use and clinical settings of PVI and the effect of changes in reimbursement. METHODS Using a 5% national sample of Medicare fee-for-service beneficiaries from 2006 to 2011, we examined age-and sex-adjusted rates of PVI by year, type of procedure, clinical setting, and physician specialty. RESULTS A total of 39,339 Medicare beneficiaries underwent revascularization for PAD between 2006 and 2011. The annual rate of PVI increased slightly from 401.4 to 419.6 per 100,000 Medicare beneficiaries (p = 0.17), but the clinical setting shifted. The rate of PVI declined in inpatient settings from 209.7 to 151.6 (p < 0.001), whereas the rate expanded in outpatient hospitals (184.7 to 228.5; p = 0.01) and office-based clinics (6.0 to 37.8; p = 0.008). The use of atherectomy increased 2-fold in outpatient hospital settings and 50-fold in office-based clinics during the study period. Mean costs of inpatient procedures were similar across all types of PVI, whereas mean costs of atherectomy procedures in outpatient and office-based clinics exceeded those of stenting and angioplasty procedures. CONCLUSIONS From 2006 to 2011, overall rates of PVI increased minimally. However, after changes in reimbursement, PVI and atherectomy in outpatient facilities and office-based clinics increased dramatically, neutralizing cost savings to Medicare and highlighting the possible unintended consequences of coverage decisions. (C) 2015 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available